Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

Treatment and Diagnosis plans to sponsor Phase I and Phase II trials of PCI-32765 in various hematologic malignancies.
  • The Phase II clinical program, designed to enable potential registrational paths in CLL, mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL), is ongoing. We anticipate that these Phase II trials will allow for Phase III enabling decisions in these indications based upon ongoing analysis of the data in the next 6-12 months.

  • As of the end of August, 2011 we enrolled 320 patients into clinical trials evaluating PCI-32765. The ongoing Phase II program currently includes the following studies:
  • PCYC-1104:  A multicenter, Phase II study of PCI-32765 in relapsed or refractory mantle cell lymphoma, including cohorts of subjects either previously treated with bortezomib or naïve to bortezomib treatment. This trial is active in several US and European sites and by the end of August, 2011 enrolled 60 patients. We have submitted a preliminary analysis of this study for consideration for the 2011 ASH meeting in December, 2011.
  • PCYC-1106:  A multicenter, open-label, Phase II study of PCI 32765 in subjects with relapsed or refractory DLBCL. This study is designed to assess the activity of PCI-32765 in two genetically distinct subtypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center (GC) subtype. This trial is active in several US sites and by the end of August, 2011 enrolled 13 patients. We expect to complete enrollment of all 60 patients by calendar Q1 2012. A separate pilot study of PCI-32765 in patients with ABC subtype DLBCL is currently being conducted at the NIH Clinical Center. An abstract detailing an interim analysis of this pilot trial has been submitted for consideration for the 2011 ASH meeting in December, 2011.
  • PCYC-1108: A Phase IB, multicenter, open-label, study of PCI 32765, in combination with intensive immune chemotherapy (FCR = fludarabine, cycl
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
    2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
    3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
    4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
    5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
    6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
    7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
    9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
    10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
    11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
    (Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
    (Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
    Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
    ... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
    ... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
    Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
    (Date:9/1/2015)... ... September 01, 2015 , ... ... for the treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, ... cap, while also demonstrating its safety when used at home to combat hair ...
    (Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... is proud to announce its new fall collection. Every customer who buys an ... part of the company’s environmental partnership with Trees for the Future, a nonprofit ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy ... their partnership with Apex Physical Therapy (Apex) is official as of ... kind, compassionate, and empathetic care to local residents from their combined eight locations ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Stress ... stress created from everyday life changes can lead to very serious, life-altering events. ... for coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic ...
    (Date:9/1/2015)... ... , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of ... has taken place at Kingsborough Community College in Brooklyn in each of the past ... Calvary, and two junior counselors who were campers themselves just a few years ago. ...
    Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3
    ... 10 Varian Medical Systems (NYSE: VAR ) announced ... year 2009 following the close of regular trading on Thursday, January ... teleconference available to all interested parties at 2:00 p.m. PT. , ... results can be accessed on January 29, 2009. The news release ...
    ... Basic government services are not being provided in Zimbabwe. ... communicable diseases are rampant. Staggering inflation and unemployment have resulted ... people remain at risk of cholera, which is being spread ... functioning sanitation services. To date, the outbreak has claimed over ...
    ... people will wait longer for ER treatment, elective procedures, ... There could be a shortage of 1,300 general surgeons ... and that shortage could increase to 6,000 by 2050, ... surgeons often perform lifesaving operations on critically injured or ...
    ... Dec. 10 The American Botanical Council (ABC) has ... http://www.themeaningoftea.com ) adoption of tea ( Camellia sinensis ). ... provide ABC financial support to ensure that abstracts (summaries) ... tea are made available within ABC,s HerbMedPro database, one ...
    ... WASHINGTON, Dec. 10 American Life League will feature two ... at their Training and Activism Week and Personhood Conference Jan. ... http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) , , ... former nurse who launched the Born Alive Truth campaign during ...
    ... third of patients with suspect scans develop the disease within ... -- Among people whose brain scans show signs of multiple ... within about five years, researchers say. , The study ... variety of reasons, including migraines or head trauma. The scans ...
    Cached Medicine News:Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 3Health News:U.S. May Soon Face Shortage of General Surgeons 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 3Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 4Health News:A.L.L. Personhood Conference Features Pro-Life New Media Stars 2Health News:MRI Can Spot Presymptomatic MS 2
    ...
    No. 1. 30 mm conventional blades. Thin well-rounded tips....
    Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
    Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
    Medicine Products: